1. Atrial hiPSC-CM as a Pharmacologic Model to Evaluate Anti-AF Drugs: Some Lessons From I Kur.
- Author
-
Schulz C, Eschenhagen T, and Christ T
- Subjects
- Humans, Animals, Potassium Channel Blockers pharmacology, Potassium Channels metabolism, Potassium Channels drug effects, Potassium Channels agonists, Heart Rate drug effects, Induced Pluripotent Stem Cells drug effects, Induced Pluripotent Stem Cells metabolism, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Atrial Fibrillation physiopathology, Atrial Fibrillation drug therapy, Atrial Fibrillation metabolism, Action Potentials drug effects, Anti-Arrhythmia Agents pharmacology, Heart Atria drug effects, Heart Atria metabolism, Heart Atria physiopathology
- Abstract
Abstract: Human induced pluripotent stem cells (hiPSC) and atrial hiPSC-derived cardiomyocytes (hiPSC-CM) have entered the arena of preclinical atrial fibrillation research. A central question is whether they reproduce the physiologic contribution of atrial selective potassium currents (such as the ultrarapid potassium current, I Kur ) to repolarization. Of note, 2 studies in single atrial hiPSC-CM reported prolongation of action potential duration by I Kur block indicating that I Kur might in fact represent a valuable target for the treatment of human atrial fibrillation. However, the results and interpretation are at odds with the literature on I Kur block in human atria and the results of clinical studies. We believe that the discrepancies indicate that experiments in single atrial CM (both adult atrial CM and atrial hiPSC-CM) might be misleading. Under particular experimental conditions, atrial hiPSC-CMs may not closely resemble the electrophysiology of the human atrium. Therefore, we recapitulate here methodological issues evaluating potential value of the I Kur as an antiarrhythmic target when investigated in animal models, in human atrial tissues, and finally in atrial hiPSC-CM., Competing Interests: C. Schulz and T. Christ have no conflict of interest. T. Eschenhagen is consultant and shareholder of Dinaqor AG., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF